Innovotech Inc. Grants Director's Options Subsequent to the Annual Meeting

(TheNewswire)

Edmonton, Alberta – TheNewswire - July 9, 2025
– Innovotech Inc. (TSX-V: IOT)(“Innovotech”) has granted stock options to its Board of Directorsas annual remuneration and recognition of their ongoing contributionsand alignment with long-term shareholder value creation.  

A total of 350,000
options have been granted to the Company’s seven directors, with
each director receiving 50,000 options. The options are exercisable at
a price of $0.33 per share, representing a 10% premium to the closing
price of the Company’s common shares on the TSX Venture Exchange on
July 9, 2025.  

About Innovotech:

Innovotech Inc.
is a diversified Canadian technology company with business operations
in a growing portfolio of specialized laboratory services,
biotechnology businesses, and proprietary intellectual property.
Innovotech Inc. manages several subsidiary companies.  Innovotech
Labs Corporation is a contract research organization that owns and
provides proprietary devices for antimicrobial testing in multiple
applications and commercializes antimicrobial silver solutions. Learn
more at www.innovotech.ca. Keystone Labs Inc. is a DEL-accredited labserving the Canadian pharmaceutical industry and industrial markets.Learn more at www.keystonelabs.ca.  Innovotech Inc. owns a 60% stake inNouLifeSciences Inc., a company holding intellectual property relatedto antioxidant molecules with potential applications in cosmetics andvarious medical conditions including neuropathies.  

Craig Milne, CEO          Innovotech Inc.

+1-604-239-1819        craig.milne@innovotech.ca

This documentmay contain forward-looking statements that are predictive in natureand subject to risks and uncertainties that cannot be predicted orquantified; consequently, actual results may differ materially frompast results and those expressed or implied by any forward-lookingstatements. Factors that could cause or contribute to such risks oruncertainties include, but are not limited to: the regulatoryenvironment including the difficulty of predicting regulatoryoutcomes; changes in the value of the Canadian dollar; the Company’sreliance on a small number of customers including governmentorganizations; fluctuations in operating results; government policiesor actions; progress and cost of clinical trials; reliance on keystrategic relationships; uncertainty related to intellectual propertyprotection and potential costs associated with its defense; theCompany’s exposure to lawsuits and other matters beyond the controlof management. Should known or unknown risks or uncertaintiesmaterialize, or should management’s assumptions prove inaccurate,actual results could vary materially from those anticipated. TheCompany undertakes no obligation to publicly make or update anyforward- looking statements, except as required by applicable law.

Neither the TSXVenture Exchange nor its Regulation Services Provider (as that term isdefined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy of this release.

###

Copyright (c) 2025 TheNewswire - All rights reserved.